Tradestie Institutional Equity Comparison Engine

AKTS vs SPRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SPRO Overall Edge

SPRO Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spero Therapeutics, Inc. Common Stock (SPRO) driven by superior Valuation, Growth & Margin, Options & Structure while AKTS counters with relative strength in Momentum & Technical. Fundamentally, AKTS trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus SPRO at N/M Forward P/E and 14.1% operating margin (-95.6% YoY). In options structure, AKTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SPRO sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SPRO
AKTS N/M vs SPRO N/M Fwd P/E
Growth & Margin Winner SPRO
Op Margin N/A vs 14.1% ยท YoY N/A vs -95.6%
Momentum & Technical Winner AKTS
1Y -26.4% vs -63.1% ยท 52W Pos 12% vs 0%
Options & Structure Winner SPRO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (24th %ile IV)
AKTS US Equity
AKTS
Institutional Equity
$16.49
-0.78% 1D
Market Cap N/A
1M Return +9.5%
1Y Return -26.38%
Forward P/E N/M
Unified AI Score
30.6 / 100 SELL
Tech 20.0 Fund 36.0 Flow 50.0 Mom 40.0
SPRO NASDAQ
Spero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.90
-9.97% 1D
Market Cap $58.8M
1M Return -18.16%
1Y Return -63.11%
Forward P/E N/M
Unified AI Score
47.8 / 100 HOLD
Tech 39.0 Fund 53.0 Flow 66.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKTS -26.38% SPRO -63.11% Spread: +38.32 pp (AKTS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKTS TTM Op. Margin: N/A SPRO TTM Op. Margin: 14.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTS vs SPRO. Trailing 12-month operating profitability (AKTS N/A vs SPRO 14.1%) and valuation multiples (AKTS N/M vs SPRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKTS (1) vs SPRO (8)
Institutional Metric AKTS SPRO Criterion Row Winner
Market Capitalization Scale N/A $58.8M Larger Scale SPRO
Trailing P/E Ratio Valuation N/M 7.2x Lower Multiple SPRO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -95.6% Higher Growth SPRO
Operating Margin (TTM) Profitability N/A 14.1% Higher Margin SPRO
Net Profit Margin Profitability N/A 15.7% Higher Margin SPRO
Return on Equity (ROE) Capital Efficiency N/A 19.2% Higher ROE SPRO
52-Week Range Position Momentum 12% ($14โ€“$34) 0% ($1โ€“$3) Stronger Trend AKTS
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 66% Vol 1.70ฮฒ ยท 65% Vol Lower Realized Risk SPRO
Unified Institutional Score Composite Signal 30.6 / 100 (SELL) 47.8 / 100 (HOLD) Higher Composite SPRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKTS vs SPRO Buy Guide
AKTS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AKTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SPRO BREAKDOWN
120d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live SPRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKTS nor SPRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.